Processes for producing stable exosome formulations
AssigneeCapricor, Inc.
InventorsMichelle Kreke, Rachel Smith, Peter Hanscome, Kiel Peck, Ahmed Ibrahim
Life of this patent
Estimating the term…
Abstract
The invention encompasses methods for generating stable exosome formulations and encompasses stable exosome formulations. The exosome formulations encompass stable liquid exosome formulations and stable lyophilized exosome formulations. In some embodiments, the exosome formulations can be generated by ultrafiltration and diafiltration. The exosome formulations can be suitable for administration to a human.
Claims15
A stable lyophilized exosome formulation suitable for administration to a human comprising at least 106 exosomes, wherein the wherein the lyophilized exosomes maintain at least 90% of the levels of miR-210 RNA and miR-146A of the exosome formulation pre-lyophilization.
A stable lyophilized exosome formulation suitable for administration to a human comprising at least 106 exosomes, wherein the lyophilized exosomes maintain at least 90% of the level of in vitro biological activity of the exosome preparation pre-lyophilization.
A stable liquid cardiosphere-derived cell (CDC) exosome formulation suitable for administration to a human comprising at least 106 CDC exosomes, wherein the exosome formulation maintains at least 75% of the levels of miR-210 RNA and miR-146A of the starting exosome formulation for 30 days at 4° C.
Dependencies are inferred from the claim text.